Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2014

View Archived Issues

Gilead Sciences begins phase Ib study of GS-9883

Intra-Cellular Therapies and Takeda terminate collaboration to develop PDE1 inhibitors

Single nucleotide mutation in NFIA gene leads to brain malformation and urinary tract defect

Eisai advances pipeline in second quarter of fiscal 2014

Chemically attenuated whole parasite blood-stage malaria vaccine approach tested in humans

IntelGenx completes pilot study of INT-0036 for schizophrenia

Protection against T. cruzi observed with ArtinM in an acute experimental infection model

Affinivax launched with funding from Bill & Melinda Gates Foundation

Altor BioScience begins development of ALT-803 for multiple myeloma

Asana BioSciences reports discovery of kinase inhibitors for cancer

OncoArendi Therapeutics discloses new cancer treatments

Sage Therapeutics synthesizes novel GABA(A) receptor modulators

Amgen reports topline secondary endpoint results from TRINOVA-1 trial

D-Pharm reports data from phase II study of THR-18 in stroke patients treated with tPA

Ruga Corp. patents new B-raf kinase inhibitors

Chinese researchers prepare and test MKK1 inhibitors

Bayer completes acquisition of Dihon Pharmaceutical Group

NicOx reports development of NO donors

Repurposing of an approved glaucoma drug for the treatment of type 2 diabetes

CXCL10 gene polymorphism associated with malaria susceptibility in Ghanaian children

MedImmune to acquire tissue biomarker analysis company

EMA accepts Oleogel-S10 MAA for review

Terumo applies for approval of skeletal myoblast sheets

Kancera selects first candidate in ROR project

USAMRIID demonstrates in vitro activity of two HemispheRx drugs against Ebola virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...